# Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

> **NCT03446144** · PHASE2 · WITHDRAWN · sponsor: **Ionis Pharmaceuticals, Inc.**

## Conditions studied

- Geographic Atrophy
- Age Related Macular Degeneration

## Interventions

- **DRUG:** IONIS-FB-Lrx
- **DRUG:** Placebo (sterline saline 0.9%)

## Key facts

- **NCT ID:** NCT03446144
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-16
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objective change, no safety or efficacy concerns
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446144, "Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03446144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*